GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Cash Flow from Operations

Shandong Boan Biotechnology Co (HKSE:06955) Cash Flow from Operations : HK$-42.8 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Jun. 2024, Shandong Boan Biotechnology Co's Net Income From Continuing Operations was HK$66.4 Mil. Its Depreciation, Depletion and Amortization was HK$30.5 Mil. Its Change In Working Capital was HK$-174.7 Mil. Its cash flow from deferred tax was HK$0.0 Mil. Its Cash from Discontinued Operating Activities was HK$0.0 Mil. Its Asset Impairment Charge was HK$0.0 Mil. Its Stock Based Compensation was HK$11.1 Mil. And its Cash Flow from Others was HK$13.4 Mil. In all, Shandong Boan Biotechnology Co's Cash Flow from Operations for the six months ended in Jun. 2024 was HK$-53.3 Mil.


Shandong Boan Biotechnology Co Cash Flow from Operations Historical Data

The historical data trend for Shandong Boan Biotechnology Co's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co Cash Flow from Operations Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
-600.68 -301.56 -225.40 -20.31

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Operations Get a 7-Day Free Trial -133.88 -97.86 -30.78 10.47 -53.30

Shandong Boan Biotechnology Co Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Shandong Boan Biotechnology Co's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Shandong Boan Biotechnology Co's Cash Flow from Operations for the quarter that ended in Jun. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-42.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Boan Biotechnology Co  (HKSE:06955) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Shandong Boan Biotechnology Co's net income from continuing operations for the six months ended in Jun. 2024 was HK$66.4 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Shandong Boan Biotechnology Co's depreciation, depletion and amortization for the six months ended in Jun. 2024 was HK$30.5 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Shandong Boan Biotechnology Co's change in working capital for the six months ended in Jun. 2024 was HK$-174.7 Mil. It means Shandong Boan Biotechnology Co's working capital declined by HK$174.7 Mil from Dec. 2023 to Jun. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Shandong Boan Biotechnology Co's cash flow from deferred tax for the six months ended in Jun. 2024 was HK$0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Shandong Boan Biotechnology Co's cash from discontinued operating Activities for the six months ended in Jun. 2024 was HK$0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Shandong Boan Biotechnology Co's asset impairment charge for the six months ended in Jun. 2024 was HK$0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Shandong Boan Biotechnology Co's stock based compensation for the six months ended in Jun. 2024 was HK$11.1 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Shandong Boan Biotechnology Co's cash flow from others for the six months ended in Jun. 2024 was HK$13.4 Mil.


Shandong Boan Biotechnology Co Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co Business Description

Traded in Other Exchanges
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li 2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co Headlines

No Headlines